WEREWOLF THERAPEUTICS, INC. Derivative, Gain (Loss) on Derivative, Net
WEREWOLF THERAPEUTICS, INC. (HOWL) reported Derivative, Gain (Loss) on Derivative, Net of $707.00 thousand for the 6-month period ending 2026-06-30, per its S-4 filed 2026-09-22.
Financial Statements › Income Statement › Other Income
us-gaap:DerivativeGainLossOnDerivativeNet · last filed 2026-09-22
- WEREWOLF THERAPEUTICS, INC. derivative, gain (loss) on derivative, net for the quarter ending 2026-06-30 was $33.00K, a 73.68% increase year-over-year.
- WEREWOLF THERAPEUTICS, INC. derivative, gain (loss) on derivative, net for the quarter ending 2026-03-31 was $674.00K, a 294.15% increase year-over-year.
- WEREWOLF THERAPEUTICS, INC. derivative, gain (loss) on derivative, net for the quarter ending 2025-12-31 was $1.85M.
- WEREWOLF THERAPEUTICS, INC. derivative, gain (loss) on derivative, net for the quarter ending 2025-09-30 was $25.00K, a 76.42% decline year-over-year.
- WEREWOLF THERAPEUTICS, INC. derivative, gain (loss) on derivative, net for fiscal 2023 was $0.00.
| Period end | Derivative, Gain (Loss) on Derivative, Net 3 month | Derivative, Gain (Loss) on Derivative, Net 6 month | Derivative, Gain (Loss) on Derivative, Net 9 month | Derivative, Gain (Loss) on Derivative, Net 12 month |
|---|---|---|---|---|
| 2026-06-30 | $33.00K derived: S-4 6 month − 10-Q 3 month · filed 2026-09-22 | $707.00K S-4 · filed 2026-09-22 | $2.56M derived: sum of 3 quarters · filed 2026-09-22 | $2.59M derived: sum of 4 quarters · filed 2026-09-22 |
| 2026-03-31 | $674.00K 10-Q · filed 2026-05-07 | $2.53M derived: sum of 2 quarters · filed 2026-09-22 | $2.55M derived: sum of 3 quarters · filed 2026-09-22 | $2.57M derived: sum of 4 quarters · filed 2026-09-22 |
| 2025-12-31 | $1.85M derived: S-4 12 month − 10-Q 9 month · filed 2026-09-22 | $1.88M derived: sum of 2 quarters · filed 2026-09-22 | $1.90M derived: sum of 3 quarters · filed 2026-09-22 | $2.07M S-4 · filed 2026-09-22 |
| 2025-09-30 | $25.00K derived: 10-Q 9 month − S-4 6 month · filed 2025-11-04 | $44.00K derived: sum of 2 quarters · filed 2026-09-22 | $215.00K 10-Q · filed 2025-11-04 | $121.00K derived: sum of 4 quarters · filed 2026-09-22 |
| 2025-06-30 | $19.00K derived: S-4 6 month − 10-Q 3 month · filed 2026-09-22 | $190.00K S-4 · filed 2026-09-22 | $96.00K derived: sum of 3 quarters · filed 2026-09-22 | $202.00K derived: sum of 4 quarters · filed 2026-09-22 |
| 2025-03-31 | $171.00K 10-Q · filed 2026-05-07 | $77.00K derived: sum of 2 quarters · filed 2026-09-22 | $183.00K derived: sum of 3 quarters · filed 2026-09-22 | $1.79M derived: sum of 4 quarters · filed 2026-09-22 |
| 2024-12-31 | -$94.00K derived: S-4 12 month − 10-Q 9 month · filed 2026-09-22 | $12.00K derived: sum of 2 quarters · filed 2026-09-22 | $1.62M derived: sum of 3 quarters · filed 2026-09-22 | $1.62M S-4 · filed 2026-09-22 |
| 2024-09-30 | $106.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $1.72M derived: sum of 2 quarters · filed 2025-11-04 | $1.72M 10-Q · filed 2025-11-04 | $1.72M derived: sum of 4 quarters · filed 2025-11-04 |
| 2024-06-30 | $1.61M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $1.61M 10-Q · filed 2025-08-14 | $1.61M derived: sum of 3 quarters · filed 2025-08-14 | $579.00K derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $0.00 10-Q · filed 2025-05-08 | $0.00 derived: sum of 2 quarters · filed 2025-05-08 | -$1.03M derived: sum of 3 quarters · filed 2025-05-08 | |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | -$1.03M derived: sum of 2 quarters · filed 2025-03-11 | $0.00 10-K · filed 2025-03-11 | |
| 2023-09-30 | -$1.03M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $0.00 10-Q · filed 2024-11-07 | ||
| 2023-06-30 | $1.03M 10-Q · filed 2024-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 |